Page last updated: 2024-12-09

2-(4-methylphenoxy)-N-[4-(2-oxazolo[4,5-b]pyridinyl)phenyl]acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

## 2-(4-methylphenoxy)-N-[4-(2-oxazolo[4,5-b]pyridinyl)phenyl]acetamide

This is a complex chemical compound with a long and descriptive name. It's important to break it down to understand its potential significance.

**Let's analyze the structure:**

* **2-(4-methylphenoxy):** This part indicates a 4-methylphenol group (a substituted phenol) connected at the 2nd position of another molecule.
* **N-[4-(2-oxazolo[4,5-b]pyridinyl)phenyl]acetamide:** This part indicates an acetamide group connected to a nitrogen atom (N). This nitrogen is part of a phenyl ring that's connected to another ring system, specifically a 2-oxazolo[4,5-b]pyridinyl group.

**Why is it important for research?**

The compound's importance lies in its **potential biological activity.** It contains several key structural features commonly found in:

* **Pharmaceuticals:** The presence of an aromatic ring system (phenyl) and a heterocyclic ring system (oxazolo[4,5-b]pyridinyl) are often seen in drugs that target various biological receptors or enzymes.
* **Bioactive molecules:** The acetamide group is frequently found in molecules with potential therapeutic applications.

**However, without additional context, it's impossible to pinpoint the exact reason for this compound's research interest.**

**Possible research areas:**

* **Drug discovery:** The compound could be a potential lead molecule for the development of new pharmaceuticals.
* **Biological studies:** Researchers might be investigating the compound's effects on specific biological processes or targets.
* **Materials science:** The compound might have interesting properties relevant to materials development.

**To fully understand the significance of this compound, one needs to know:**

* **The research context:** What specific research question or hypothesis is this compound being investigated for?
* **The experimental methods used:** What kind of biological or chemical experiments are being conducted with this compound?
* **The results obtained:** What specific effects or observations are being made with this compound?

By providing more context, it's possible to understand the real importance of this compound in research.

Cross-References

ID SourceID
PubMed CID1094286
CHEMBL ID1577023
CHEBI ID120400

Synonyms (22)

Synonym
2-(4-methylphenoxy)-n-(4-[1,3]oxazolo[4,5-b]pyridin-2-ylphenyl)acetamide
MLS000062723 ,
smr000071260
OPREA1_190080
OPREA1_194468
AK-968/12269376
STK240549
2-(4-methylphenoxy)-n-[4-([1,3]oxazolo[4,5-b]pyridin-2-yl)phenyl]acetamide
CHEBI:120400
AKOS000468883
MLS002540839
VU0040002-5
HMS2362J13
CHEMBL1577023
2-(4-methylphenoxy)-n-(4-oxazolo[4,5-b]pyridin-2-ylphenyl)acetamide
2-(4-methylphenoxy)-n-[4-(2-oxazolo[4,5-b]pyridinyl)phenyl]acetamide
2-(4-methylphenoxy)-n-[4-([1,3]oxazolo[4,5-b]pyridin-2-yl)phenyl]ethanamide
cid_1094286
bdbm53557
Q27208241
2-(4-methylphenoxy)-n-(4-{[1,3]oxazolo[4,5-b]pyridin-2-yl}phenyl)acetamide
333774-00-8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1,3-oxazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.63100.044717.8581100.0000AID485294
Chain A, HADH2 proteinHomo sapiens (human)Potency0.79430.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency0.79430.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency3.54810.177814.390939.8107AID2147
Chain A, CruzipainTrypanosoma cruziPotency3.98110.002014.677939.8107AID1476
thioredoxin reductaseRattus norvegicus (Norway rat)Potency12.58930.100020.879379.4328AID588456
ClpPBacillus subtilisPotency2.51191.995322.673039.8107AID651965
ATAD5 protein, partialHomo sapiens (human)Potency24.96780.004110.890331.5287AID624247; AID624252; AID624253; AID720565
Microtubule-associated protein tauHomo sapiens (human)Potency0.44670.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency11.22020.011212.4002100.0000AID1030
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.62280.001815.663839.8107AID894
ras-related protein Rab-9AHomo sapiens (human)Potency5.62340.00022.621531.4954AID485297
DNA polymerase eta isoform 1Homo sapiens (human)Potency7.94330.100028.9256213.3130AID588591
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
Guanine nucleotide-binding protein GHomo sapiens (human)Potency5.62341.995325.532750.1187AID624288
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
tyrosine-protein phosphatase non-receptor type 7 isoform 2Homo sapiens (human)IC50 (µMol)100.00000.100012.726563.0000AID521
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
beta-2 adrenergic receptorHomo sapiens (human)EC50 (µMol)0.03610.00161.87598.4400AID588763; AID588775
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]